Previous cohort studies reported a CD8 T-cell increase and a reduction of CD4/CD8 ratio in patients living with HIV (PLWHIV) and in treatment with dual therapies. Data are still lacking on dual therapies containing new drugs such as dolutegravir (DTG). Aim of the present work is to evaluate CD4/CD8 dynamics in patients in DTG based dual therapies (DTG-DUAL) and compare them with patients in DTG containing triple therapies.
Improvement of CD4/CD8 ratio in experienced patients switching to dolutegravir based dual therapies.
Pellicanò G. F.;
2019-01-01
Abstract
Previous cohort studies reported a CD8 T-cell increase and a reduction of CD4/CD8 ratio in patients living with HIV (PLWHIV) and in treatment with dual therapies. Data are still lacking on dual therapies containing new drugs such as dolutegravir (DTG). Aim of the present work is to evaluate CD4/CD8 dynamics in patients in DTG based dual therapies (DTG-DUAL) and compare them with patients in DTG containing triple therapies.File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
